Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heme Iron Polypeptide vs Ionic Iron Tolerance
NCT01865175Phase 4Withdrawn
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Jan 2016
- Primary completion
- May 2016
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of heme iron polypeptide in iron deficiency anemia (IDA), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Gastrointestinal tolerance at 4 weeks. Planned start Jan 2016; status: withdrawn.
02
Drugs
heme iron polypeptide
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT01865175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01865175.